Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosite On Track To Earn First Rapid Stroke Assay Approval With PMA Filing

This article was originally published in The Gray Sheet

Executive Summary

Biosite expects to present data comparing its Triage Stroke Panel to computed axial tomography (CAT) to FDA's Clinical Chemistry & Toxicology Devices Panel this year

You may also be interested in...



NIH/Biosite Licensing Agreement Proposed For Atherosclerosis Gene Markers

Biosite is contemplating exclusively licensing genetic markers from the National Institutes of Health for the early diagnosis of coronary artery disease

NIH/Biosite Licensing Agreement Proposed For Atherosclerosis Gene Markers

Biosite is contemplating exclusively licensing genetic markers from the National Institutes of Health for the early diagnosis of coronary artery disease

Cardiac Markers Clash For Hospital, Lab Space: Biosite Triages R&D Projects

Biosite's pursuit of additional disease markers for its Triage immunoassay meter will continue unabated this summer, even as the company defends BNP test market share from newcomer Abbott Labs and imminent rival Dade Behring

Related Content

UsernamePublicRestriction

Register

MT021400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel